B-cell Chronic Lymphoid Malignancies Markers

Study of Cell Markers of Marginal Zone Lymphoma and Other B-cell Chronic Lymphoid Malignancies

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04952974

Acronym

MALYZOMA-II

Enrollment

420

Registered

2021-07-07

Start date

2021-06-14

Completion date

2023-03-30

Last updated

2021-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Lymphocytic Leukemia, Follicular Lymphoma, Hairy Cell Leukemia, Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma

Keywords

Chronic B-cell malignancies, Flow cytometry, Biomarkers, Statistical algorithms

Brief summary

Lymphoid chronic B-cell malignancies are frequent pathologies that affect adults, with a very variable prognosis and treatment (some of them can remain untreated). The diagnosis of these malignancies relies on the study of the morphology of tumoral cells and the expression by these cells of several markers, mainly via a technical approach called flow cytometry. Because the markers currently used remain imperfect, additional ones are needed for an accurate diagnosis that affect both prognosis and treatment. In addition, because numerous markers are used at the diagnosis, there is a need of tools that synthetize the multi-dimensional structure of the data obtained. The primary purpose of this study is to detect new markers that can be of help for the diagnosis of Marginal Zone Lymphoma and other B-cell chronic lymphoid malignancies. The secondary purpose of this study is to obtain a statistical algorithm that allow a good prediction of the different sub-types of chronic B-cell malignancies mainly using the results of flow cytometry.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients over 18 years-old with of Marginal Zone Lymphoma and other B-cell chronic lymphoid malignancies * patients that gave their informed consent for the conservation of blood or bone marrow cells (primary objective 1) * patients that gave their informed consent for the retrospective use of their clinical and biological data

Exclusion criteria

* patients under guardianship or curatorship * patients who did not gave their consent for the use of their cells and/or data

Design outcomes

Primary

Measure	Time frame
Retrospective study of laboratory data from patients with B lymphoid hemopathy, mainly lymphoma in the marginal zone	2 years

Countries

France

Contacts

Primary ContactLaurent MAUVIEUX, MD, PhD

laurent.mauvieux@chru-strasbourg.fr33 3 88 12 75 27

Backup ContactSaïd CHAYER, PhD, HDR

said.chayer@chru-strasbourg.fr33 3 88 11 66 90

Outcome results